| EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent N Mottet, RCN van den Bergh, E Briers, T Van den Broeck, ... European urology 79 (2), 243-262, 2021 | 1998 | 2021 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 842* | 2018 |
| EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer P Cornford, RCN van den Bergh, E Briers, T Van den Broeck, ... European urology 79 (2), 263-282, 2021 | 782 | 2021 |
| 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 WP Fendler, M Eiber, M Beheshti, J Bomanji, F Ceci, S Cho, F Giesel, ... European journal of nuclear medicine and molecular imaging 44, 1014-1024, 2017 | 754 | 2017 |
| Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for … JJ Morigi, PD Stricker, PJ van Leeuwen, R Tang, B Ho, Q Nguyen, ... Journal of nuclear medicine 56 (8), 1185-1190, 2015 | 631 | 2015 |
| Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation E Zamagni, F Patriarca, C Nanni, B Zannetti, E Englaro, A Pezzi, ... Blood, The Journal of the American Society of Hematology 118 (23), 5989-5995, 2011 | 571 | 2011 |
| Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE I Virgolini, V Ambrosini, JB Bomanji, RP Baum, S Fanti, M Gabriel, ... European journal of nuclear medicine and molecular imaging 37, 2004-2010, 2010 | 495 | 2010 |
| A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the … E Zamagni, C Nanni, F Patriarca, E Englaro, P Castellucci, O Geatti, ... Haematologica 92 (1), 50-55, 2007 | 413 | 2007 |
| Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA MF Bozkurt, I Virgolini, S Balogova, M Beheshti, D Rubello, C Decristoforo, ... European journal of nuclear medicine and molecular imaging 44, 1588-1601, 2017 | 409 | 2017 |
| Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review T Van den Broeck, RC Van Den Bergh, N Arfi, T Gross, L Moris, E Briers, ... European urology 75 (6), 967-987, 2019 | 396 | 2019 |
| ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging A Sundin, R Arnold, E Baudin, JB Cwikla, B Eriksson, S Fanti, N Fazio, ... Neuroendocrinology 105 (3), 212-244, 2017 | 387 | 2017 |
| Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ... Annals of Oncology 26 (8), 1589-1604, 2015 | 376 | 2015 |
| Role of 99mTc-DPD Scintigraphy in Diagnosis and Prognosis of Hereditary Transthyretin-Related Cardiac Amyloidosis C Rapezzi, CC Quarta, PL Guidalotti, C Pettinato, S Fanti, O Leone, ... JACC: Cardiovascular Imaging 4 (6), 659-670, 2011 | 351 | 2011 |
| EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) C Kratochwil, WP Fendler, M Eiber, R Baum, MF Bozkurt, J Czernin, ... European journal of nuclear medicine and molecular imaging 46, 2536-2544, 2019 | 326 | 2019 |
| Detection and localization of prostate cancer: correlation of 11C-choline PET/CT with histopathologic step-section analysis M Farsad, R Schiavina, P Castellucci, C Nanni, B Corti, G Martorana, ... Journal of Nuclear Medicine 46 (10), 1642-1649, 2005 | 322 | 2005 |
| 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? F Ceci, C Uprimny, B Nilica, L Geraldo, D Kendler, A Kroiss, J Bektic, ... European journal of nuclear medicine and molecular imaging 42, 1284-1294, 2015 | 306 | 2015 |
| Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT V Prasad, V Ambrosini, M Hommann, D Hoersch, S Fanti, RP Baum European journal of nuclear medicine and molecular imaging 37, 67-77, 2010 | 299 | 2010 |
| Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours V Ambrosini, P Tomassetti, P Castellucci, D Campana, G Montini, ... European journal of nuclear medicine and molecular imaging 35, 1431-1438, 2008 | 299 | 2008 |
| 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors V Ambrosini, D Campana, L Bodei, C Nanni, P Castellucci, V Allegri, ... Journal of Nuclear Medicine 51 (5), 669-673, 2010 | 296 | 2010 |
| METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based … AR Padhani, FE Lecouvet, N Tunariu, DM Koh, F De Keyzer, DJ Collins, ... European urology 71 (1), 81-92, 2017 | 286 | 2017 |
Francesco CeciDirector of Nuclear Medicine Department - IEO European Institute of Oncology IRCCS, Milan, ItalyVerified email at ieo.it
